Evaluate The Effect Of Serum Containing Bushenyijingfang On The Blood-brain Barrier And The Clinical Study Of Bushenyijingfang On Mild Cognitive Impairment

Objective:To evaluate the effect of serum containing Bushenyijingfang on the blood-brain barrier and explore the effect of Bushenyijingfang for treating mild cognitive impairment in clinical.Methods:Experimental method:Embryonic rat brain microvascular endothelial cells and astrocytes were cultured in vitro, then determine the transmesothelial electrical resistance.Blood brain barrier model of co-culture of endothelial cells and astrocytes was established by using Transwell cell culture pool,and the 5μmol/L Aβ1-42 was added in the model.The experiments were divided into the following groups:the model group,the low, medium and high dose group of serum containing Bushenyijingfang and the blank group without Aβ1-42, then detected and compared the permeability of fluorescein sodium in each group.Design criteria used in this study is randomized, open and parallel.We collected a total of 60 cases of clinical data, and randomly divided into two groups:the treatment group of 30 cases and the control group of 30 cases.The treatment group was given oral Bushenyijing decoction,200ml each time, two times a day.The control group was given oral donepezil,5mg each time, once a day.Observation period of the two groups was both six months.Six months later,calculated and compared TCM syndrome score, MMSE score and ADAS-cog score results to analysis the clinical efficacy before and after the treatment.Results Experimental results:Compared with the blank group, the permeability of sodium fluorescein in the model group increased significantly (P<0.01).Compared with the model group, the permeability of fluorescein sodium in the low and medium dose group of serum containing Bushenyijingfang was significantly lower (P<0.05).The results showed that each dose group of serum containing Bushenyijingfang had a protective effect on the blood brain barrier damage induced by AP1-42, and the protective effect was more obvious in middle and low dose groups.This study observed three indicators:MMSE score, ADAS-cog score and TCM syndrome score before and after the treatment.TCM syndrome score,MMSE score and ADAS-cog score before and after the treatment in the two groups showed statistically significant (P<0.05).The results showed that both the treatment group and the control group could improve the cognitive function and behavioral ability of patients with mild cognitive impairment.Conclusion:The results showed that serum containing Bushenyijingfang had a protective effect on the blood brain barrier damage induced by AP1-42.Effect of Bushenyijingfang and donepezil on the treatment of mild cognitive impairment is the same.But the effect of Bushenyijingfang is better than donepezil in improving the TCM syndromes and no obvious adverse reaction.